Corcept Therapeutics Incorporated reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with net product revenue reaching $761.4 million, up from $675.0 million in 2024 and $482.4 million in 2023. This 13% year-over-year growth was primarily driven by a 37% increase in sales volume, although it was partially offset by a 17.7% decrease in average selling price due to the introduction of an authorized generic version of its product, Korlym. The company noted that revenue could have been higher if its primary specialty pharmacy vendor had met demand more effectively.
In terms of operational developments, Corcept transitioned its specialty pharmacy services from Optime Care to Curant Health Georgia, LLC, effective January 8, 2026. This change is part of a strategic move to enhance service delivery for patients with hypercortisolism, a condition treated by Korlym. The company has also been active in clinical research, with the CATALYST study revealing that 23.8% of patients with difficult-to-control diabetes were found to have hypercortisolism, leading to further trials to optimize treatment options.
Corcept's research and development expenses totaled $254.9 million for 2025, reflecting a focus on advancing its product pipeline, including relacorilant, a selective cortisol modulator. However, the FDA issued a Complete Response Letter (CRL) for relacorilant in December 2025, requiring additional evidence of efficacy before approval. The company is currently working with the FDA to determine the best path forward for this product. Additionally, Corcept is pursuing new trials for relacorilant in combination with chemotherapy for ovarian cancer, with a PDUFA date set for July 11, 2026.
The company’s workforce has grown to 730 employees as of December 31, 2025, and it continues to invest in its sales and marketing efforts to support the commercialization of its products. Corcept's financial outlook remains cautiously optimistic, with expectations for continued revenue growth and increased research and development spending in 2026. However, the company faces challenges from competition, particularly from generic versions of Korlym, and ongoing regulatory scrutiny that could impact its operations and financial results.
About CORCEPT THERAPEUTICS INC
Corcept Therapeutics develops medications that modulate cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its core products include Korlym and relacorilant for hypercortisolism, with ongoing trials for cancer, liver disease, ALS, and metabolic conditions. The company leverages proprietary cortisol modulators, patents, and strategic collaborations to address unmet medical needs in hormone regulation and cancer therapy.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.